Eye injection study for diabetes-related vision loss ends early
NCT ID NCT07228559
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single injection of avoralstat into the eye for people with diabetic macular edema, a condition that causes vision loss in diabetes. Only 3 adults took part before the study was stopped early. The main goal was to check safety and see if the drug might help reduce swelling in the retina.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigative Site 1
Sydney, New South Wales, Australia
-
Investigative Site 2
Sydney, New South Wales, Australia
-
Investigative Site 3
Sydney, New South Wales, Australia
-
Investigative Site 4
Adelaide, South Australia, Australia
-
Investigative Site 5
Melbourne, Victoria, Australia
-
Investigative Site 6
Sacramento, California, 95825, United States
-
Investigative Site 7
Katy, Texas, 77494, United States
-
Investigative Site 8
The Woodlands, Texas, 77384, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
- New syringe could simplify High-Dose eye treatment
- Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy